<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979120</url>
  </required_header>
  <id_info>
    <org_study_id>ISROTH20033</org_study_id>
    <nct_id>NCT01979120</nct_id>
  </id_info>
  <brief_title>Validation of the &quot;ApneaScan&quot; Algorithm for the Detection of Sleep Disordered Breathing in Chronic Heart Failure</brief_title>
  <acronym>VASA</acronym>
  <official_title>Validation of the &quot;ApneaScan&quot; Algorithm for the Detection of Sleep Disordered Breathing in Patients With Stable Symptomatic Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Christoph Schukro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Austrian Agency for Health and Food Safety (AGES)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective observational multi-centre study for the validation of the ApneaScan algorithm
      (integrated in ICD devices (with or without cardiac resynchronization therapy function) of
      the &quot;Incepta&quot; series for the screening of sleep disordered breathing in patients with stable
      symptomatic chronic heart failure, using portable polygraphy monitoring device (&quot;Embletta
      Gold&quot;) as reference for the Apnea-Hypopnea-Index (AHI).

      Secondary objectives are the detection of severe sleep disordered breathing in patients with
      clinically indicated in-laboratory polysomnography, as well as correlations of the AHI
      detected by ApneaScan with other clinical endpoints like mortality, hospitalization, atrial
      fibrillation and ventricular arrhythmia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Apnea-Hypopnea-Index</measure>
    <time_frame>1 night</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apnea-Hypopnea-Index &gt;/= 30 (in-laboratory polysomnography)</measure>
    <time_frame>1 night</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ICD therapies (i.e. shock or anti-tachycardia pacing)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>atrial fibrillation</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>routine B-type natriuretic peptide</measure>
    <time_frame>1 night</time_frame>
    <safety_issue>No</safety_issue>
    <description>only if applicable!</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sleep-disordered Breathing</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>only 1 cohort!</arm_group_label>
    <description>All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable symptomatic chronic heart failure and implanted ICD/CRT-D of the
        &quot;INCEPTA&quot; series
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Patient´s written informed consent

          -  Patients with a cardiac rhythm management device (ICD with or without cardiac
             resynchronization therapy function) of the &quot;Incepta&quot; series (including the ApneaScan
             algorithm) already implanted for at least 8 weeks (corresponding to the duration of
             the leads´ healing process); in order to standardize the enrollment period, inclusion
             should be effected between the first (the earliest 8 weeks after implantation) and
             the second routine control of ICD-function (the latest 9 months after implantation)

          -  Stable symptomatic chronic heart failure for either ischemic or non-ischemic reason
             (moderately to severely impaired systolic left ventricular function with NYHA-class
             II to III) under optimal pharmacological treatment (according to guidelines 2012 of
             the European Society of Cardiology)

        Exclusion Criteria:

          -  Unstable heart failure (NYHA-class IV) or asymptomatic chronic heart failure
             (including patients with very mild exercise induced dyspnea, i.e. NYHA-class I)

          -  Patients already treated for sleep apnea syndrome (i.e. continuous positive airway
             pressure mask) or chronic obstructive pulmonary disease with GOLD-class IV (i.e.
             long-term oxygen therapy)

          -  A limited AHI detection by the ApneaScan algorithm until the planned inclusion
             (randomly defined by &lt;50% of countable AHI detection-points within the last 2 weeks).

          -  Patients with limited mobility due to orthopedic, neurologic or oncologic diseases
             (because of restricted assessment of exercise induced dyspnea)

          -  Patients on dialysis (either acute or chronic)

          -  Alcoholism or regular intake of hypnotics

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Schukro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Schukro, MD, PhD</last_name>
    <phone>+43140400</phone>
    <phone_ext>4614</phone_ext>
    <email>christoph.schukro@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schukro, MD, PhD</last_name>
      <phone>+43140400</phone>
      <phone_ext>4614</phone_ext>
      <email>christoph.schukro@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Schukro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Jakl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hietzing Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reinhard Achleitner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMZO</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang Cozzarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wiener Neustadt Hospital</name>
      <address>
        <city>Wiener Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Teubl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes centre NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johannes Brachmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reinbek Hospital</name>
      <address>
        <city>Reinbek</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert Nägele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu University</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shin-Ichi Ando, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoshifumi Takata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tottori University</name>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Masahiko Kato, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juntendo University School of Medicine</name>
      <address>
        <city>Urayasu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Takatoshi Kasai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haran Burri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>November 3, 2013</lastchanged_date>
  <firstreceived_date>November 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Christoph Schukro</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Sleep-disordered breathing</keyword>
  <keyword>Chronic heart failure</keyword>
  <keyword>Implantable cardioverter-defibrillator</keyword>
  <keyword>Apnea-Hypopnea-Index</keyword>
  <keyword>Portable Polygraphy Monitoring</keyword>
  <keyword>Polysomnography</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
